clinical trial · NCT06106022
A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease
Gastroesophageal Reflux DiseaseVonoprazan
brief summary
The aim of this study is to evaluate the pharmacokinetic (PK) profile of vonoprazan (10 or 20 mg once daily \[QD\]) in children ≥ 6 to \< 12 years of age who have symptomatic Gastroesophageal Reflux Disease (GERD).
started
Nov 1, 2023
primary completion
Apr 16, 2024
completion
Apr 29, 2024
last updated
Dec 19, 2024
official title
A Phase 1, Randomized, Parallel-group, Open-label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan (10 or 20 mg Once Daily) in Children Aged ≥ 6 to < 12 Years Who Have Symptomatic Gastroesophageal Reflux Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol